Patrick Baeuerle as featured speaker at Cancer conference Oct. 20-22, 2010 CA-SF
Online, August 28, 2010 (Newswire.com) - SAN FRANCISCO, CA - Dr. Patrick Baeuerle , Vice President of Micromet, to present as a featured speaker at GTCbio's 2nd Annual Cancer Targets and Therapeutics Conference, part of the 6th Modern Drug Discovery and Development Summit on Oct. 20-22, 2010 in San Francisco, CA.
Dr. Baeuerle will give a presentation on "BiTE Antibody-Engaged T-Cells for Cancer Therapy." MT110 is a novel BiTE antibody recognizing the pan-carcinoma antigen EpCAM (CD326), which is expressed on a large variety of human adenocarcinoma, and on cancer-initiating or stem cells derived therefore. MT110 is in a phase 1 study with gastrointestinal and lung cancer patients. A murine EpCAM/CD3-specific version of the BiTE antibody, called muS110, has shown a robust therapeutic window in mice with no damage to EpCAM-expressing normal epithelia. Additional BiTE antibodies specific for EGFR, CD33, EphA2, CEA, Her-2/neu, FAP-alpha, IGF-1R and c-Met have been generated and shown to have a high potency of redirected target cell lysis.
Dr. Baeuerle has served as Micromet's Chief Scientific Officer since October 1998. From February 1996 to September 1998, Mr. Baeuerle headed the drug discovery activities of Tularik Inc. in South San Francisco, CA, as Director, Drug Discovery. From October 1994 to February 1996, Mr. Baeuerle served as a full Professor and Chairman of Biochemistry at the Medical Faculty of Freiburg University, Germany. According to a survey by the Institute for Scientific Information (ISI, Philadelphia, PA, USA), Mr. Baeuerle was Germany's most frequently cited biomedical scientist of the past decade, and 38th worldwide. In addition, Mr. Baeuerle is the first recipient of the Prix Europeen de l'Avenir and an elected member of the European Molecular Biology Organization (EMBO). He was appointed Honorary Professor of Immunology at the University of Munich in 2000.
Also presenting at the Cancer Targets and Therapeutics conference are prestigious organizations including Genentech, Harvard Medical School, AstraZeneca, Roche, Amgen, National Cancer Institute, Novartis, MedImmune, Boston University, Pfizer, and other leaders in cancer targets and therapeutics. The three-day meeting also includes a plenary keynote session with speakers from Theravance, Roche, Human Genome Sciences, and Novartis. For more information, visit www.gtcbio.com.